To the Editor:We would like to correspond and share ideas about the publication “Early administration of Anti-SARS-Co-2 Monoclonal Antibodies Prevents Severe Covid-19 in Kidney Transplant Patients?.” Gueguen et al.
noted that “The early use of MoAb in KTRs with a mild form of Covid-19 largely improved outcomes in KTRs.” We agree that the antibodies might be useful. However, the course of COVID-19 might be different in different individuals. The effect of the concurrent alternative therapy or vaccination and underlying health status or personal illness should be discussed. In addition, there is a rapid change of genetic epidemiology of the SARS-CoV-2. During the study period in the current study, there might be a change of variant of the pathogen and it might also be related to the clinical usefulness of the studied monoclonal antibodies. Finally, because asymptomatic COVID-19 is not uncommon, some patients might already have had previous asymptomatic COVID-19 and thus had background circulating antibodies. This is also a possible confounding factor to determine the effectiveness of the monoclonal antibodies in the present study.